2Garcia-Sanz R, Montoto S, Torrequebrada A, et al, Waldenstrom macroglobulinaemia: presenting features and outcome in a series with 217 cases[J]. Br J Haematol, 2001, 115(3): 575-582.
3Owen RG, Treon SP, Al-Katib A, et al .Clinicopathological definition of Waldenstrom's maeroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Maeroglobulinemia[J]. Semin Oneol, 2003, 30(2): 110-115.
4Owen RG, Barrans SL, Richards SJ, et al. Waldenstrom macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors[J]. Am J Clin Pathol, 2001, 116 (3): 420-428.
5Konoplev S, Medeiros LJ, Bueso-Ramos CE, et al. Immunophenotypic profile of lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia[J]. Am J Clin Pathol, 2005, 124 (3): 414-420.
6Ocio EM, Schop RF, Gonzalez B, et al. 6q deletion in Waldenstrom macroglobulinemia is associated with features of adverse prognosis [J]. Br J Haematol, 2007, 136(1): 80-86.
7Anagnostopoulos A, Zervas K, Kyrtsonis M, et al. Prognostic value of serum beta2-microglobulin in patients with Waldenstrom's macroglobulinemia requiring treatment [J]. Clin Lymphoma Myeloma, 2006, 7(3): 205-209.
8Ghobrial IM, Fonseca R, Gertz MA, et al. Prognostic model for disease -specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom maeroglobulinaemia[J]. Br J Haematol, 2006, 133(2): 158-164.
9Tamburini J, Levy V, Chaleteix C, et al. Fludarabine plus eyclophosphamide in Waldenstrom's macroglobulinemia: results in 49 patients[J]. Leukemia, 2005, 19(10): 1831-1834.
10Weber DM, Dimopoulos MA, Delasalle K, et al. 2- Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia[J]. Semin Oncol, 2003, 30(2): 243-247.
